← Back to Search

Antiplatelet Agent

Aspirin for Preeclampsia (ASAPP Trial)

Phase 2
Recruiting
Led By Megan C Oakes, MD MSCI
Research Sponsored by MemorialCare Health System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Preeclampsia with severe features diagnosed during delivery admission, as defined by ACOG criteria.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks postpartum
Awards & highlights
No Placebo-Only Group

Summary

This trial will evaluate whether taking aspirin after childbirth can help women with preeclampsia recover quickly and safely.

Who is the study for?
This trial is for women who have just given birth and were diagnosed with severe preeclampsia during delivery. They must be receiving care from the Long Beach Memorial Ob/Gyn or Maternal-Fetal Medicine clinic.
What is being tested?
The study is testing if low-dose aspirin can help women recover faster from severe preeclampsia after childbirth by lowering a protein linked to high blood pressure in pregnancy.
What are the potential side effects?
Low-dose aspirin may cause side effects such as stomach pain, heartburn, nausea, and an increased risk of bleeding. However, many people take it without any problems.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I was diagnosed with severe preeclampsia during my delivery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks postpartum
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks postpartum for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Reduction in sFlt-1
Secondary study objectives
Adherence
Anti-hypertensive therapy
Enrollment feasibility
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Standard blood pressure control plus aspirin 81 mgExperimental Treatment1 Intervention
Standardized postpartum blood pressure control Aspirin 81 mg by mouth x 1 week post-delivery
Group II: Standard blood pressure controlActive Control1 Intervention
Standardized postpartum blood pressure control
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Aspirin 81Mg Ec Tab
2023
Completed Phase 4
~120

Find a Location

Who is running the clinical trial?

MemorialCare Health SystemLead Sponsor
20 Previous Clinical Trials
2,469 Total Patients Enrolled
University of California, IrvineOTHER
562 Previous Clinical Trials
1,932,426 Total Patients Enrolled
Megan C Oakes, MD MSCIPrincipal InvestigatorMiller Children's and Women's Hospital, Long Beach/ MemorialCare Medical Center
~38 spots leftby Nov 2025